Recognizing World Alzheimer's Day

09.23.13 | By

As the nation recognizes World Alzheimer’s Day this Saturday, the federal government announced that it is awarding a $33.2 million grant to test an Alzheimer’s medicine in pre-symptomatic seniors (60 to 75 year olds) with two copies of the AD gene.  According to a 

Giving Patients Hope

09.20.13 | By

As Senior VP of Communications Matt Bennett noted on the Catalyst this week, years of hard work go into developing and testing new medicines, and this perseverance has resulted in great progress in clinical trial research.

FDA Spends $182k to Monitor Social Media While Biopharma Industry Waits for Social Media Guidance

09.20.13 | By

In this austere fiscal environment, I must admit to being a little surprised by the news that the Food and Drug Administration (FDA) is spending $182,000 on a tool to monitorwhat people are saying about the Agency on social media. 

Clinical Trials Data Sharing in Europe

09.20.13 | By

A new paper released this week highlights issues surrounding the discussions on clinical trial data & The paper Clinical Trials and Data Transparency: The Public Interest Case, highlights specific problems to the current draft European Medicines Agency (EMA). Among the problems highlighted were gaps in the protection of patient privacy, further bureaucratization of an already bureaucratic  system and conflicting policies on regulatory data protection. 

A Story of Hope - Ellie McGinn

09.19.13 | By

Delivering hope to millions of patients is the foundation of our industry. While the word 'hope' is highly personal to each patient, a common thread exists that unites all of us regardless of age, geographic location or socio-economic status. Without it, we would not be in a position to advance critical research that provides innovative new medicines to patients across the globe. By all accounts, 'hope' is the driver that keeps us looking forward.

Alzheimer's Research and Clinical Trials

09.19.13 | By

There have been a number of media reports over the last week about the challenges surrounding Alzheimer’s research.

Having Conversations on the Biopharmaceutical Pipeline

09.18.13 | By

There are more than 5,000 new medications in the research and development pipeline. Some of these medications may one day result in effective treatments for diseases and conditions that exact a tremendous personal and financial toll on patients around the country and the world.

Conversations Wrap Up

09.17.13 | By

Biopharmaceutical scientists work daily to identify and develop potential preventative and therapeutic medicines for some of the most difficult conditions and diseases, with the unified goal of helping people live longer and healthier lives. Rarely have we been more successful at achieving this goal than with the development and global utilization of vaccines  

2013 Research and Hope Awards -- Robert Hugin's Remarks

Thank you John and thank you Anita [Brickman – local TV reporter who is event MC] for hosting tonight’s celebration.

Let me echo John’s welcome and thank our partners – all representing important elements of the health care ecosystem of innovation – as well as our media partners.

Your support has been crucial to the success of this wonderful event.

Tonight, I stand between you, a good dinner, the far more inspiring Dr. Tom Frieden and the reason we’re all here… honoring the achievements of doctors Fu, Lowy and Schiller and GlaxoSmithKline’s malaria vaccine team.

A Healthy Dose of Dedication and Compassion

09.16.13 | By

It doesn't take long to understand why biopharmaceutical research companies have conducted more than 800 clinical trials in Montana.


Subscribe to RSS - Opinion